UBS Group
HSCS icon

UBS Group’s Heart Test Laboratories HSCS Stock Holding History

UBS Group’s Portfolio HSCS Stock Details HSCS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.6K Sell
5,812
-664
-10% -$1.36K ﹤0.01% 8344
2026
Q1 		$16.3K Buy
6,476
+508
+9% +$1.48K ﹤0.01% 8080
2025
Q4 		$18.4K Buy
+5,968
New +$17.7K ﹤0.01% 7843
2025
Q2 		– Sell
-2,625
Closed -$7.4K – 10510
2025
Q1 		$7.4K Buy
2,625
+1,320
+101% +$4.41K ﹤0.01% 8828
2024
Q4 		$4.99K Buy
1,305
+624
+92% +$2.14K ﹤0.01% 8705
2024
Q3 		$3.3K Sell
681
-5,715
-89% -$20.9K ﹤0.01% 8290
2024
Q2 		$33.3K Buy
+6,396
New +$50.8K ﹤0.01% 6996
2023
Q2 		– Sell
-11
Closed -$1.09K – 9208
2023
Q1 		$1.09K Sell
11
-9
-45% -$1.22K ﹤0.01% 8816
2022
Q4 		$1.64K Buy
20
+2
+11% +$313 ﹤0.01% 9822
2022
Q3 		$2K Sell
18
-25
-58% -$4.27K ﹤0.01% 9730
2022
Q2 		$8K Buy
+43
New +$8.31K ﹤0.01% 8308

Other funds holding HSCS

TA
TFB Advisors Overland Park, Kansas $227M AUM 26.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ASW
Astoria Strategic Wealth Conroe, Texas $438M AUM 16.79% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group's HSCS Position: Q2 2026 in Review

UBS Group reduced its Heart Test Laboratories (HSCS) stake by 10% in Q2 2026, selling an estimated $1.36K and leaving 5,812 shares worth $14.6K. The position accounts for ﹤0.01% of the portfolio, ranked #8344.

UBS Group first reported a position in HSCS in Q2 2022 and has held it in 11 quarters since. The position peaked at $33.3K in Q2 2024. 16 funds tracked by Wall St. Rank hold HSCS as of Q2 2026.

  • UBS Group held 5,812 shares of Heart Test Laboratories worth $14.6K as of Q2 2026.
  • UBS Group sold 664 Heart Test Laboratories shares in Q2 2026, an estimated $1.36K.
  • Heart Test Laboratories made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8344 holding.
  • UBS Group first reported a position in Heart Test Laboratories in Q2 2022 and has held it in 11 quarters since.
  • UBS Group's Heart Test Laboratories position peaked at $33.3K in Q2 2024.
  • 16 funds tracked by Wall St. Rank held Heart Test Laboratories as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.